Potent Inducer Of Apoptosis Research Articles

Novel quinoxaline-based VEGFR-2 inhibitors to halt angiogenesis

Vascular endothelial growth factor receptor-2 is a dynamic target for therapeutic intervention in various types of cancer. This study was aimed at exploring the VEGFR-2 inhibitory activity of a novel library of quinoxalin-2-one derivatives such as 3-furoquinoxaline carboxamides, 3-pyrazolylquinoxalines, and 3-pyridopyrimidyl-quinoxalines. Among them, 6c, 7a, and 7d-f produced remarkable cytotoxicity against HCT-116 (IC50′s 4.28–9.31 µM) and MCF-7 (IC50′s 3.57–7.57 µM) cell lines using the MTT assay and doxorubicin (DOX) as a reference standard. Interestingly, results of cytotoxicity towards the human fibroblast cell line WI38 revealed that these hits demonstrated higher selectivity indices towards both HCT-116 (SI 8.69–23.19) and MCF-7 (SI 9.48–27.80) than DOX, SI 0.72 and 0.90, respectively. Then, these hits were subjected to a mechanistic study; they showed direct inhibition of VEGFR-2. Impressively, compound 7f displayed 1.2 times the VEGFR-2 inhibitory activity of sorafenib. The antiangiogenic potential of 7f was proved via lowering the level of VEGF-A, than that of control. It as well, exhibited scratch closure percent of 61.8%, compared with 74.5% of control at 48 hrs, indicating the potential anti-migratory effect of the compound 7f. It significantly increased the expression of tumor suppressor gene (p53) on MCF-7 cells by almost 18 folds and upregulated the caspase-3 level by 10.7 folds, compared to the control. Cell cycle analysis revealed cell cycle arrest at G2/M together with a PreG increase which indicated apoptosis induction potential. Annexin V-FITC apoptosis results proposed the two modes of cell death (apoptosis and necrosis) as an inherent mechanism of cytotoxicity of compound 7f. Molecular docking further supported the mechanism showing the affinity of target compounds for VEGFR-2 active site. Moreover, physicochemical and drug-like properties were assessed from the ADME properties.

Synthesis and Biological Evaluation of α-Tocopherol Derivatives as Potential Anticancer Agents

α-Tocopheryl succinate (α-TS) and α-tocopheryloxyacetic acid (α-TEA) are potent inducers of apoptosis in cancer cells and efficient suppressors of tumors in experimental model cancer cell lines. They exhibit selective cytotoxicity against tumor cells and very limited or no toxicity toward nonmalignant cells. In the present work, a series of new α-tocopherol derivatives were synthesized as analogs of α-TS and α-TEA. The cytotoxic activity of obtained compounds was tested using three human cancer cell lines, including chronic lymphoblastic leukemia (CEM), breast adenocarcinoma (MCF7), cervical adenocarcinoma (HeLa), and normal human fibroblasts (BJ). The introduction of an alkyl substituent into the ether-linked acetic acid moiety in α-TEA increased anticancer activity. α-Tocopheryloxy-2-methylpropanoic acid with two additional geminal methyl groups was more active against CEM cells compared to α-TEA and non-toxic to normal cells. In order to acquire a deeper understanding of the biological activity of synthesized compounds, a molecular docking study was also conducted. Our research confirmed that vitamin E derivatives are interesting and valuable compounds in terms of their potential therapeutic use as anticancer agents.

Antiproliferative effects of Australian native plums against the MCF7 breast adenocarcinoma cells and UPLC-qTOF-IM-MS-driven identification of key metabolites

The rich and unique phytochemical profiles of Australian native fruits are attributed to the intense climatic conditions of the island. Of these native fruits, the Kakadu plum (KP; Terminalia ferdinandiana), Illawarra plum (IP; Podocarpus elatus), and Davidson's plum (DP; Davidsonia pruriens) have been increasingly used in the food industry. However, their phytochemical profiles and bioactivity are not well explored. This study examined the antiproliferative activity of water and ethanol extracts of KP, IP and DP against the MCF7 breast adenocarcinoma cells using the Alamar blue assay. The potential induction of apoptosis and reactive oxygen species (ROS) generation in the MCF7 cells by the active extracts was examined. The most potent extracts were analysed using biochemometric and liquid chromatography-mass spectrometry (LC-MS) driven metabolomic identification. A dose-dependent antiproliferative activity of KP-water (IC50 = 239.9 μg/mL), KP-ethanol (IC50 = 254.7 μg/mL), and IP-ethanol (IC50 = 521.7 μg/mL) was observed. All other extracts (IP-water, DP-water, DP-ethanol) showed IC50 values > 3000 μg/mL. The three potent extracts at 3000 μg/mL induced apoptosis (P < 0.05) but did not increase the production of ROS in the MCF7 cells. The metabolomic identification revealed an abundance of tannin, flavonoids, and triterpenoid compounds as potential anticancer metabolites in the KP extracts. Further mechanistic investigations are warranted to formulate Australian plum-based dietary interventions.

Retracted: Isolation and purifications of an ambuic acid derivative compound from marine algal endophytic fungi Talaromyces flavus that induces apoptosis in MDA-MB-231 cancer cells.

In recent years, there has been a lot of buzz about the possibilities of marine microflora as a source of new therapeutic drugs. The strong anti-tumor potency of compounds found in marine resources reflects the ocean's enormous potential as a source of anticancer therapeutics. In this present investigation, an ambuic acid derivative anticancer compound was isolated from Talaromyces flavus, and its cytotoxicity and apoptosis induction potential were analyzed. T. flavus was identified through morphological and molecular analysis. The various organic solvent extracts of T. flavus grown on different growth mediums were evaluated for cytotoxicity on different cancer cell lines. The potent cytotoxicity was shown in the ethyl acetate extract of a fungal culture grown in the M1-D medium for 21 days. Furthermore, the anticancer compound was identified using preparative thin layer chromatography, followed by its purification in significant proportions using column chromatography. The spectroscopic and chromatographic analysis revealed that the structure of the purified molecules was an ambuic acid derivative. The ambuic acid derivative compound showed potent cytotoxicity on MDA-MB-231 (breast cancer cells) with an IC50 value of 26 μM and induced apoptosis in the MDA-MB-231 cells in a time-dependent and reactive oxygen species-independent manner.

β-Carboline-α-aminophosphonate Derivative: A Promising Antitumor Agent for Breast Cancer Treatment.

Breast cancer is the most common type of cancer and the leading cause of cancer mortality among women worldwide. Considering the limitations of the current treatments available, we analyzed the in vitro cytotoxic potential of ((4-Fluoro-phenyl)-{2-[(1-phenyl-9H-β-carboline-3-carbonyl)-amino]-ethylamino}-methyl)-phosphonic acid dibutyl ester (BCP-1) in breast cancer cells (MCF-7 and MDA-MB-231) and in a non-tumor breast cell line (MCF-10A). BCP-1 has an α-aminophosphonate unit linked to the β-carboline nucleus, and the literature indicates that compounds of these classes have high biological potential. In the present study, the mechanism of action of BCP-1 was investigated through methods of spectrofluorimetry, flow cytometry, and protein expression analysis. It was found that BCP-1 inhibited the proliferation of both cancer cell lines. Furthermore, it induced oxidative stress and cell cycle arrest in G2/M. Upregulation of apoptosis-related proteins such as Bax, cytochrome C, and caspases, as well as a decrease in the anti-apoptotic protein Bcl-2, indicated potential induction of apoptosis in the MDA-MB-231 cells. While in MCF-7 cells, BCP-1 activated the autophagic death pathway, which was demonstrated by an increase in autophagic vacuoles and acidic organelles, in addition to increased expression of LC3I/LC3II and reduced SQSTM1/p62 expression. Further, BCP-1 demonstrated antimetastatic potential by reducing MMP-9 expression and cell migration in both breast cancer cell lines. In conclusion, BCP-1 is a promising candidate for breast cancer chemotherapy.

Novel Property Cytotoxicity and Mechanism of Food Preservative Brevilaterins against Human Gastric Cancer Cells.

Brevilaterins, antimicrobial peptides produced by Brevibacillus laterosporus, are regarded as excellent food preservatives and are popular as antimicrobial applications. Recent research has uncovered their potent cytotoxic effects against diverse cancer cells, thereby underscoring the pressing need for more extensive and intensive investigations into this use. In this study, we explored their novel function in inducing cytotoxicity to cancer cells and systematically investigated the mechanism of action of Brevilaterin B/C (BB/BC) in vivo. Proliferation, membrane permeability, and apoptotic rate were evaluated using CCK-8 assay, LDH assay, and Annexin V-FITC/PI kits. ROS levels and mitochondrial membrane potential were detected using the fluorescent probe DCFH-DA and JC-1. Our results demonstrated that both BB and BC at concentrations of 4-6 µg/mL significantly inhibited the proliferation and migration of gastric cancer cells BGC-823. Treatment with 4 µg/mL of BB/BC rapidly increased LDH levels in the supernatant of BGC-823 cells, leading to further investigation of the mechanism of apoptosis. We found that the apoptotic rate of BGC-823 cells significantly increased upon treatment with BB/BC, demonstrating their potent induction of apoptosis. BB/BC-induced ROS production in BGC-823 cells impaired their growth and induced apoptosis, indicating a close association between apoptosis and ROS elevation. Additionally, JC-1 aggregates rapidly accumulated after treatment with 4 µg/mL of BB/BC, suggesting changes in mitochondrial membrane potential and early apoptosis. Taken together, our findings revealed that BB and BC exhibit significant anticancer effects against gastric cancer cells, highlighting the promising potential of Brevilaterins as anticancer agents.

Abstract 4905: Anticancer activity and paraptosis induction of novel bipyridine-silver(I) compounds against resistant colorectal and ovarian cancer cell lines

Abstract Background: Platinum-based anticancer drugs (e.g. Carboplatin and Oxaliplatin) are frequently applied in chemotherapy regimens against several types of cancer including ovarian carcinoma (OC) and colorectal carcinoma (CRC). However, intrinsic or acquired tumor resistance severely limit their clinical application. Here, we investigated the anticancer activity of several novel silver(I) 2,2’-bipyridine derivatives, containing either triphenylphosphane (PPh3) or 1,2-bis(diphenylphosphino)ethane (dppe) ligands and tested their potential to overcome platinum resistance. Methods: Cytotoxicity and cross resistance profiles of the newly synthesized compounds were tested against two OC models (SKOV-3 and MES-OV), a CRC model (HCT-116) and their corresponding sublines resistant to carboplatin or oxaliplatin, as well as non-malignant fibroblasts (F331) via an MTT-based cell viability assay after 72 h continuous drug exposure. Moreover, the intracellular levels of silver were measured via ICP-MS. In addition, thioredoxin reductase (TrxR) inhibition properties, impact on cell cycle distribution and apoptosis induction potential were investigated via multiple molecular biological methods. Morphological changes induced by the silver compounds were characterized via spinning disk confocal microscopy. Results: All tested compounds displayed pronounced anticancer activity and cancer cell selectivity. Moreover, cell intrinsic resistance to carboplatin or oxaliplatin was not impacting on the cytotoxic activity of the compounds. Noteworthy, MES-OV and HCT-116 cells showed exceptional sensitivity to several silver(I) 2,2’-bipyridine derivatives with a 1,2-bis(diphenylphosphino)ethane (dppe) (AP-compounds). This sensitivity was not based on enhanced drug uptake, pronounced TrxR inhibition nor apoptosis induction or cell cycle arrest. In contrast, hypersensitive cells displayed pronounced endoplasmic reticulum (ER)-derived vesicles together with multiple others hallmarks of paraptotic cell death. Conclusion: Our findings did not only demonstrate that the new silver compounds were unaffected by cancer cell intrinsic resistance mechanisms to platinum-based chemotherapy, but also indicated a high vulnerability of tumor (sub)types towards these bipyridine silver complexes. This hypersensitivity is based on the induction of paraptosis, a novel form of programmed cell death. To summarize, these silver compounds represent a new class of promising anticancer drugs, which demand further preclinical development. Citation Format: Alessia Stefanelli, Ricardo G. Teixeira, Adhan Pilon, Rebecca Warmers, Ingo Ott, Christian R. Kowol, Anamaria Brozovic, Ana Isabel Tomaz, Andreia Valente, Petra Heffeter. Anticancer activity and paraptosis induction of novel bipyridine-silver(I) compounds against resistant colorectal and ovarian cancer cell lines. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4905.

Abstract 1570: Novel Myc-dependent compound DL78 selectively induces mitotic catastrophe and cell death in high grade serous ovarian cancer

Abstract While the rates of new cases and deaths for high grade serous ovarian cancer (HGSC) have declined steadily in the past decade, HGSC remains the fifth leading cause of cancer death in women. As many patients succumb to chemoresistance, there is a need to uncover novel targeted drugs. One way to do so is by drug repurposing. A computational screen, DrugPredict, led to the discovery that amiodarone, an antiarrhythmic, is a potent apoptosis-inducer and Myc-degrader in numerous patient-derived ovarian cancer cell lines. In search of a more selective, but less toxic compound, structure-activity relationship was applied to identify DL78. Due to its structural differences, DL78 is considered to be independent of amiodarone. DL78 lacks hERG activity, retains Myc regulation, and gains selective anticancer properties. This compound produces significant cell death selectively in patient-derived HGSC cells, including isogenic cisplatin-resistant lines, but does not harm non-transformed fallopian tube cells. Cancer cells treated with DL78 arrest prior to anaphase and showcase microtubule abnormalities and upregulation of mitotic regulators. The prolonged arrest leads to loss of Myc, mitotic catastrophe, and apoptosis selectively in the HGSC cells, while fallopian tube cells can cycle normally. DL78’s activity is confirmed to be dependent on Myc expression because targeted inhibition of Myc decreases its potency and prevents the DL78-induced cell cycle arrest. Finally, pharmacokinetic analysis shows that DL78 saturates the tumor following intraperitoneal injection, yet drug concentrations in the blood and liver present at normal levels. Overall, these phenotypes do not show with amiodarone treatment, suggesting that structurally different DL78 performs through a different mechanism. Further classification of this tumor-selective compound may reveal targeted ovarian cancer vulnerabilities. Citation Format: Jessica Teitel, Michele Cusato, Margaret Farah, Agharnan Gandhi, Pil Lee, Andrew White, John Takyi-Williams, Bo Wen, Andre Monterio Da Rocha, Analisa DiFeo. Novel Myc-dependent compound DL78 selectively induces mitotic catastrophe and cell death in high grade serous ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1570.

An Insight into In Vitro Antioxidant, Antimicrobial, Cytotoxic, and Apoptosis Induction Potential of Mangiferin, a Bioactive Compound Derived from Mangifera indica

Due to their low cost, toxicity, and health risks, medicinal plants have come to be seen as useful products and sources of biologically active compounds. Mangifera indica L., a medicinal plant with a long history, has a high bioactive metabolites content. Mangiferin (C19H18O11) is primary isolated from M. indica's leaves, which has many pharmacological benefits. In this investigation, ultrasonic-assisted extraction with ethanol as the extraction solvent was applied to obtain mangiferin from a local type of M. indica leaves. HPLC was performed after a dichloromethane-ethyl acetate liquid-liquid fractionation method. Further, UV-vis, FTIR, and NMR spectroscopy were utilized to elucidate the structure. Interestingly, purified mangiferin displayed promising antimicrobial efficacy against a diverse variety of fungal and bacterial pathogens with MICs of 1.95-62.5 and 1.95-31.25 µg/mL, respectively. Time-kill patterns also showed that mangiferin had both bactericidal and fungicidal action. Furthermore, it exhibited strong radical dosage-dependent scavenging activity (IC50 = 17.6 μg/mL) compared to vitamin C (Vc, IC50 = 11.9 μg/mL), suggesting it could be developed into a viable antioxidant agent. To our delight, the IC50 values of mangiferin for the MCF-7 and HeLa cell lines were 41.2 and 44.7 μg/mL, respectively, from MTT cell viability testing, and it was less harmful when tested against the noncancerous cell line. Notably, it significantly induced cell apoptosis in MCF-7 cells by 62.2-83.4% using annexin V-FITC/PI labeling. Hence, our findings suggest that mangiferin can be used in the medical industry to create therapeutic interventions and medication delivery systems for society.

Chrysin promotes Cisplatin-induced apoptosis via oxidative DNA damage in oral squamous cell carcinoma

Chrysin is an apigenin analog with high therapeutic potential by modulation of apoptotic signaling pathways, improving conventional chemotherapy's effectiveness. In this study, we introduced novel evidence that the Chrysin effect with Cisplatin intensely induced cell death through DNA damage in SCC-25 and CAL-27 of oral squamous cell carcinoma (OSCC). The result of Chrysin and Cisplatin alone or in combination with cell proliferation was assessed using the MTT assay. The expression levels of 8-Hydroxy-2′-deoxyguanosine (8-OXO-dG) were analyzed using an enzyme-linked immunosorbent assay (ELISA). DCFH-DA fluorescence dye was utilized to measure reactive oxygen species (ROS) formation. ELISA cell death and caspase 8 activity assays were used to measure the apoptosis rate in these cells. Chrysin significantly stimulates the cytotoxic activity of Cisplatin. Besides, the co-treatment of Chrysin plus Cisplatin significantly increased the expression levels γ-H2AX in both cell lines. Besides, this combined treatment considerably improved ROS levels and significantly down-regulated the antioxidant enzyme expression. Moreover, Chrysin treatment led to the enhancement of Cisplatin-induced apoptosis in OSCC cell lines when compared to either Chrysin or Cisplatin treated cells. Chrysin and Cisplatin co-treatment improved cytotoxicity via the increased levels of ROS production, which results in oxidative DNA damage and leads to potent apoptosis induction in tumor cells. Generally, this co-treatment could propose a therapeutic approach that hopefully promotes patients' clinical outcomes of OSCC. These data confirm the chemo-sensitizer effect of Chrysin in OSCC cells.

Reversal of Multidrug Resistance by Symmetrical Selenoesters in Colon Adenocarcinoma Cells.

Recently, selenium containing derivatives have attracted more attention in medicinal chemistry. In the present work, the anticancer activity of symmetrical selenoesters was investigated by studying the reversal of efflux pump-related and apoptosis resistance in sensitive and resistant human colon adenocarcinoma cells expressing the ABCB1 protein. The combined effect of the compounds with doxorubicin was demonstrated with a checkerboard assay. The ABCB1 inhibitory and the apoptosis-inducing effects of the derivatives were measured with flow cytometry. Whole transcriptome sequencing was carried out on Illumina platform upon the treatment of resistant cells with the most potent derivatives. One ketone and three methyl ester selenoesters showed synergistic or weak synergistic interaction with doxorubicin, respectively. Ketone selenoesters were the most potent ABCB1 inhibitors and apoptosis inducers. Nitrile selenoesters could induce moderate early and late apoptotic processes that could be explained by their ABCB1 modulating properties. The transcriptome analysis revealed that symmetrical selenoesters may influence the redox state of the cells and interfere with metastasis formation. It can be assumed that these symmetrical selenocompounds possess toxic, DNA-damaging effects due to the presence of two selenium atoms in the molecule, which may be augmented by the presence of symmetrical groups.

2,2-Diphenethyl Isothiocyanate Enhances Topoisomerase Inhibitor-Induced Cell Death and Suppresses Multi-Drug Resistance 1 in Breast Cancer Cells.

We previously reported that phenethyl isothiocyanate (PEITC), a dietary-related compound, can rescue mutant p53. A structure-activity relationships study showed that the synthetic analog 2,2-diphenylethyl isothiocyanate (DPEITC) is a more potent inducer of apoptosis than natural or synthetic ITCs. Here, we showed that DPEITC inhibited the growth of triple-negative breast cancer cells (MDA-MB-231, MDA-MB-468, and Hs578T) expressing "hotspot" p53 mutants, structural (p53R280K, p53R273H) or contact (p53V157F), at IC50 values significantly lower than PEITC. DPEITC inhibited the growth of HER2+ (p53R175H SK-BR-3, p53R175H AU565) and Luminal A (p53L194F T47D) breast cancer (BC) cells harboring a p53 structural mutant. DPEITC induced apoptosis, irrespective of BC subtypes, by rescuing p53 mutants. Accordingly, the rescued p53 mutants induced apoptosis by activating canonical WT p53 targets and delaying the cell cycle. DPEITC acted synergistically with doxorubicin and camptothecin to inhibit proliferation and induce apoptosis. Under these conditions, DPEITC delayed BC cells in the G1 phase, activated p53 canonical targets, and enhanced pS1981-ATM. DPEITC reduced the expression of MDR1 and ETS1. These findings are the first report of synergism between a synthetic ITC and a chemotherapy drug via mutant p53 rescue. Furthermore, our data demonstrate that ITCs suppress the expression of cellular proteins that play a role in chemoresistance.

Valorization of Polypore Mushroom Phellinus fastuosus by Analyzing Antioxidative, Antiproliferative and Apoptosis Induction Potential

Valorization of Polypore Mushroom Phellinus fastuosus by Analyzing Antioxidative, Antiproliferative and Apoptosis Induction Potential

Investigation of the apoptosis induction potential of synthetic sorafenib-derived compounds in breast cancer cells

هدف: سرطان از جمله مهمترین بیماری­های قرن حاضر است که افراد بسیاری در سراسر جهان به آن مبتلا می­باشند و ضمن افزایش شیوع این بیماری، هنوز درمان مناسبی برای آن پیدا نشده است. در این بین سرطان پستان شایع­ترین سرطان و همچنین علت اصلی مرگ و میر ناشی از سرطان در زنان در سراسر جهان است. محققان بدنبال یافتن راهکارهای درمانی سرطان، ترکیبات دارویی بسیاری را علیه سرطان­های مختلف سنتز کرده و اثرات آ­نها را مورد مطالعه قرار می­دهند. سورافنیب یک مهار کننده­ی اوره مولتی­کیناز است که موجب القای آپوپتوزیس و مهار آنژیوژنز و تکثیر سلول­های سرطانی می­گردد. همچنین آزمایشاتی جهت بررسی عملکرد آن در درمان سایر سرطان­ها نیز انجام شده است. مشتقاتی از سورافنیب نیز سنتز شده و مورد بررسی قرار گرفته­اند. در تحقیق حاضر اثر ضد سرطانی یکی از مشتقات سورافنیب به نام (2E,2´E)-2,2´-(1,4-فنیلن­بیس (متانیلیدن)بیس(N-(4-کلرو-3-(تری­فلوروم اتیل)فنیل)هیدرازین کربوکسامید) که به اختصار SO-D-3 نامیده شد، علیه سه رده­ی سلولی سرطان پستان مورد ارزیابی قرار گرفت.مواد و روش­ها: سه رده­ی سلولی سرطان پستان شامل MCF7، 4T1 و MDA تهیه شده و در محیط کشت RMPI کشت داده شدند. سلول­ها با غلظت­های 25/31، 5/62، 125، 250، 500، 1000 و 2000 میکرومولار از SO-D-3 تیمار شدند و میزان زنده­مانی آن­ها با استفاده از تست MTT طی زمان­های 24، 48 و 72 ساعت مورد ارزیابی قرار گرفت. القای آپوپتوز توسط SO-D-3 در سلول­های سرطانی مورد مطالعه، از طریق فلوسایتومتری بررسی گردید. همچنین سطح پروتئین­های Hsp70 و Casp8 به‫عنوان پروتئین­های دخیل در آپوپتوز با استفاده از روش وسترن بلات مطالعه شد. نتایج حاصل با استفاده از نرم افزار SPSS از نظر آماری تجزیه و تحلیل شدند.نتایج: نتایج حاصل از تست MTT نشان داد که تیمار سلول­های سرطانی به‫طور معنی‫داری موجب کاهش زنده­مانی این سلول­ها نسبت به شاهد می‫شود. میزان IC50 برای سلول­های MDA-MB-231 به‫طور قابل توجهی کمتر از سلول­های MCF7 و 4T1 در 24 ساعت بود (4/157 میکرومولار برای MDA-MB-231 در مقایسه با 8/843 میکرومولار برای MCF7 و 1212 میکرومولار برای 4T1). با این حال، تفاوت با افزایش زمان تیمار کاهش یافت (47/77 میکرومولار و 38/23 میکرومولار برای MDA-MB-231، 3/107 میکرومولار و 69/36 میکرومولار برای MCF7، و 63/83 میکرومولار و 58/16 میکرومولار برای 4T1 به‫ترتیب در 48 ساعت و 72 ساعت). آنالیز فلوسایتومتری نشان داد که در سلول­های تیمار شده با SO-D-3، سلول­های آپوپتوتیک افزایش معناداری پیدا کرده بودند. بررسی سطح پروتئین­ها با استفاده از تکنیک وسترن بلات نیز نشان داد که پروتئین HSP70 در سلول­های MCF7 و 4T1 کاهش معناداری داشته است. از طرفی در سلول­های 4T1 و MDA سطح پروتئین Casp8 به طور معناداری افزایش یافته بود.نتیجه­گیری: نتایج تحقیق حاضر نشان داد که SO-D-3 می­تواند به‫طور وابسته به‫زمان موجب مرگ سلول‫های سرطانی پستان شود. آزمایش‫های بعدی نیز نشان داد که SO-D-3 این عمل را از طریق القای آپوپتوز اعمال می­کند. بنابراین با توجه به نتایج حاصل از تحقیق حاضر، می­توان SO-D-3 را به‫عنوان یک ترکیب دارای خاصیت ضد سرطانی بالقوه معرفی نمود که قادر است با کاهش Hsp70 و تغییر بیان Casp8 دخیل در مسیر خارجی آپوپتوزیس، موجب مرگ سلول­های سرطانی پستان شود.

Inhibition of Colorectal Cancer Cell Proliferation by Treatment with Itadori Leaf Extract.

Treatment with itadori extract inhibited the growth of mouse colon cancer cells (Colon-26) in mice. In addition, it induced DNA fragmentation and caspase 3/7 activation in Colon-26 cells, suggesting potent induction of apoptosis. Itadori extracts are rich in neochlorogenic acid and rutin and also contain quercetin and piceatannol. These polyphenols are thought to be involved in the observed DNA fragmentation and caspase 3/7 activation in colon cancer cells and may thus have anticancer effects. There is hence scope for development of the leaf of itadori, which currently has only a few known uses, as a novel anti-tumor therapeutic.

IKKα kinase silencing increases doxorubicin-induced apoptosis through regulation of oxidative DNA damage response in colon cancer cells.

The inhibitor of kappa B kinase alpha (IKKα) is demonstrated to be involved in the various aspects of cancer biology, from its initiation, to progression, metastasis, and drug resistance. The aim of this study was to investigate the role of IKKα in doxorubicin (DOX)-mediated induction in apoptosis in SW-480 colon cancer cells. Cells were transfected with siRNA against IKKα and treated with DOX. MTT assay was applied to measure SW-480 cell proliferation. The mRNA levels of γ-H2AX within cells were assessed by qRT-PCR. 8-Hydroxy-2'-deoxyguanosine was measured by ELISA. The formation of intracellular reactive oxygen species (ROS) was detected by fluorometry. The antioxidant activities of some enzymes were also determined. For evaluation of apoptosis, ELISA assay was applied. IKKα silencing dramatically increased the doxorubicin cytotoxic effects. In addition, IKKα silencing substantially overexpressed γ-H2AX in SW-480 cells. Furthermore, upon IKKα silencing, the levels of ROS were elevated and the antioxidant defense system was significantly weakened. In addition, IKKα silencing led to the enhancement of apoptotic cells in doxorubicin-treated SW-480 cells. Co-treatment of IKKα and doxorubicin led to the enhanced cellular cytotoxicity via robosting ROS formation, inducing oxidative DNA damage, and decreasing cellular antioxidant defense, and finally potent apoptosis induction in cancer cell lines.

Apoptosis induction in leukemic cells by L-asparaginase preparation from Bacillus indicus: bench-scale production, purification and therapeutic application.

With the emergence of multiple side effects on the usage of commercial L-asparaginase formulations, keen interest is provoked to investigate new sources of L-asparaginases that possess antileukemic properties with minimal side effects. The present study reports the cost-effective bench-scale production, homogeneity purification and apoptosis induction potential of a new L-asparaginase preparation from Bacillus indicus against human leukemia cells. The enzyme is highly specific toward the natural substrate L-asparagine. The study initiated with the enzyme production using cost-effective substrates in which a 3.28-fold enhancement of enzyme activity was achieved in comparison with an unoptimized medium using the central composite experimental design approach. The scale-up of the process in a 3.7-L batch bioreactor resulted in 16.42 ± 0.17IU/mL of L-asparaginase activity in 24h. The crude extracellular enzyme was purified to homogeneity using anion exchange chromatography followed by gel filtration chromatography. A single band of approximately 35kDa molecular weight was obtained on SDS-PAGE, while native PAGE analysis confirmed it to be a tetramer of four identical subunits. The circular dichroism spectroscopic study revealed the α + β mixed type of secondary structure with 38.7% α-helices and 27.4% β pleated sheets. The antitumor toxicity exhibited on the MOLT-4 leukemia cells by the new L-asparaginase was revealed using the MTT assay and acridine orange/propidium iodide dual staining for live/dead cells. The flow cytometry analysis established the potential of the purified L-asparaginase to induce the apoptotic cell death mechanism in MOLT-4 leukemia cells. Conclusively, the L-asparaginase of Bacillus indicus is a highly promising candidate that can be introduced as a new enzyme therapeutic against various leukemia disorders.

Cytotoxic activity of Cape Fynbos against triple-negative breast cancer cell line

• Erica glabella, Hippia frutescens and Salvia africana-lutea ( methanol), and Eriocephalus racemosa ( hexane) extracts IC 50 at < 30 µg/mL • Eriocephalus racemosa induced 21.48±2.86% apoptosis similar to cisplatin 23.72±4.36%. • Metabolite profiling of Salvia africana-lutea extract revealed the presence of phosphatidylcholines, triterpenoids, oxepane and 7-O-methylated flavonoids derivatives. Breast cancer is a leading cause of cancer-related deaths in women globally. Even though a plethora of treatments are available, most patients experience adverse effects which affect their quality of life. The aim of this study was to investigate the utility of nine Fynbos plants ( Erica magnisylvae E.G.H Oliv., Erica canescens J.C. Wendl. , Erica coccinea L. , Erica glabella Thunb. , Erica corifolia L. , Eriocephalus racemosa L. , Hippia frutescens L., Salvia africana-lutea L. and an unknown Fynbos plant) in treating breast cancer. Solvent extraction of fynbos plants was performed, and crude extracts were evaluated against MDA-MB 231 cancer cell line to determine the cytotoxic activity with the mode of cell death confirmed using flow cytometry. Antioxidant activity and mass spectrometry-based metabolite profiling were performed to characterize and identify the phytochemical constituents of the extracts. The methanol extracts from E. glabella ., H. frutescens and S. africana-lutea and the hexane extract from E. racemosa showed promising cytotoxic activities in the screening phase and thus were further evaluated to determine their 50% inhibitory concentrations (IC 50 ) which were found to be < 30 µg/mL. Flow cytometry analysis of treated MDA-MB 231 cells revealed promising results for the hexane crude extract (leaves) of E. racemosa and stem methanol crude extract of H. frutescens which induced apoptosis in MDA-MB-231 cancer cell line, similar to the reference drug cisplatin. Metabolite profiling of S. africana-lutea extract, the most potent apoptosis inducer in this study, revealed the presence of phosphatidylcholines, triterpenoids, oxepane and 7-O-methylated flavonoids derivatives. It was concluded that E. racemosa and S. africana-lutea are excellent candidates for further development of therapeutic agents in the fight against cancer, given the pressing need for novel efficacious agents.

Nature-inspired new isoindole-based Passerini adducts as efficient tumor-selective apoptotic inducers via caspase-3/7 activation

The development of novel therapeutics promoting selective tumor elimination is the mainstay of clinical oncology. Emerging insights into tumor targeting reveal caspases activation, especially caspase-3, as a personalized anticancer strategy. Our on-going cancer research has exploited Passerini α-acyloxy carboxamides as caspase-3/7-dependent apoptotic inducers. Herein, we adopted scaffold hopping design to introduce new series of isoindole-based Passerini adducts as caspase-3/7 activators inspired by natural alkaloids from Lion's Mane mushroom promoting caspase-3-mediated apoptosis. Additional pharmacophoric motifs of lead caspase activators were merged into the tailored Passerini skeleton. The rationally designed adducts were synthesized utilizing one-pot reaction of the novel 4-(2′-phthalimido)phenylisonitrile 5, cyclohexanone and miscellaneous carboxylic acids under Passerini conditions. All derivatives were screened for their antiproliferative activities against lung A549, colorectal Caco-2 and breast MDA-MB 231 cancer cells compared to normal fibroblasts utilizing MTT assay. Most of the evaluated derivatives were superior to 5-fluorouracil. The 2-(1H-indol-3-yl)acetate derivative (8a) recorded the highest anticancer potency (IC50 = 0.04–0.11 μM) and selectivity (SI = 42.59–125.53), followed by the 3-(4-(trifluoromethyl)phenyl)acrylate (8m), the 2-(phenylsulfonyl)glycinate (8q), and the 2-(2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy)acetate (8c) derivatives, respectively. The four hits induced cancer cells apoptosis (up to 57.99%) via caspase-3/7 activation (up to 5.47 folds). Apoptosis-inducing factor1 (AIF1) quantification assay excluded their caspase-independent apoptosis induction potential via AIF1 signaling pathway. Docking simulations clarified the possible binding modes of the hit compounds with XIAP BIR2 domain; the specific receptor of caspase-3/7 activators, and aided identifying their structural determinants of activity. Finally, their practical LogP, efficiency metrics, in silico ADMET profiling were drug-like.

Simultaneous crosslinking of CD20 and CD38 receptors by drug-free macromolecular therapeutics enhances B cell apoptosis in vitro and in vivo.

Drug-Free Macromolecular Therapeutics (DFMT) is a new paradigm in macromolecular therapeutics that induces apoptosis in target cells by crosslinking receptors without the need of low molecular weight drugs. Programmed cell death is initiated via a biomimetic receptor crosslinking strategy using a two-step approach: i) recognition of cell surface antigen by a morpholino oligonucleotide-modified antibody Fab' fragment (Fab'-MORF1), ii) followed by crosslinking with a multivalent effector motif - human serum albumin (HSA) grafted with multiple complementary morpholino oligonucleotides (HSA-(MORF2)x). This approach is effective in vitro, in vivo, and ex vivo on cells from patients diagnosed with various B cell malignancies. We have previously demonstrated DFMT can be applied to crosslink CD20 and CD38 receptors to successfully initiate apoptosis. Herein, we show simultaneous engagement, and subsequent crosslinking of both targets ("heteroreceptor crosslinking"), can further enhance the apoptosis induction capacity of this system. To accomplish this, we incubated Raji (CD20+; CD38+) cells simultaneously with anti-CD20 and anti-CD38 Fab'-MORF1 conjugates, followed by addition of the macromolecular crosslinker, HSA-(MORF2)x to co-cluster the bound receptors. Fab' fragments from Rituximab and Obinutuzumab were employed in the synthesis of anti-CD20 bispecific engagers (Fab'RTX-MORF1 and Fab'OBN-MORF1), whereas Fab' fragments from Daratumumab and Isatuximab (Fab'DARA-MORF1 and Fab'ISA-MORF1) targeted CD38. All heteroreceptor crosslinking DFMT combinations demonstrated potent apoptosis induction and exhibited synergistic effects as determined by Chou-Talalay combination index studies (CI<1). In vitro fluorescence resonance energy transfer (FRET) experiments confirmed the co-clustering of the two receptors on the cell surface in response to the combination treatment. The source of this synergistic therapeutic effect was further explored by evaluating the effect of combination DFMT on key apoptosis signaling events such as mitochondrial depolarization, caspase activation, lysosomal enlargement, and homotypic cell adhesion. Finally, a xenograft mouse model of CD20+/CD38+ Non Hodgkin lymphoma was employed to demonstrate in vivo the enhanced efficacy of the heteroreceptor-crosslinking DFMT design versus single-target systems.